157 related articles for article (PubMed ID: 37361592)
1. Chemotherapy for the initial treatment of metastatic prostate adenocarcinoma and neuroendocrine carcinoma at diagnosis: real world application and impact in the SEER database (2004 -2018).
Wang S; Yin M; Wang P; Folefac E; Monk JP; Tabung FK; Clinton SK
Front Oncol; 2023; 13():1165188. PubMed ID: 37361592
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract][Full Text] [Related]
3. Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Prostate; 2021 Dec; 81(16):1374-1381. PubMed ID: 34523162
[TBL] [Abstract][Full Text] [Related]
4. Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients.
Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Front Oncol; 2021; 11():778858. PubMed ID: 34888250
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study.
Zhu J; Liang X; Wu D; Chen S; Yang B; Mao W; Shen D
Medicine (Baltimore); 2021 Apr; 100(15):e25237. PubMed ID: 33847621
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytoreductive surgery on outcomes of metastatic appendiceal carcinoma: a real-world, population-based study.
Abdel-Rahman O
J Comp Eff Res; 2020 Apr; 9(6):431-439. PubMed ID: 32253936
[No Abstract] [Full Text] [Related]
9. Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysis.
Pan X; Yang W; Wen Z; Li F; Tong L; Tang W
J Gynecol Oncol; 2020 Nov; 31(6):e80. PubMed ID: 33078590
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis.
Oweira H; Petrausch U; Helbling D; Schmidt J; Mannhart M; Mehrabi A; Schöb O; Giryes A; Decker M; Abdel-Rahman O
World J Gastroenterol; 2017 Mar; 23(10):1872-1880. PubMed ID: 28348494
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
Cattrini C; Cerbone L; Rubagotti A; Zinoli L; Latocca MM; Messina C; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2019 Aug; 17(4):e724-e732. PubMed ID: 31160193
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
14. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
16. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Site-Specific Metastases and Therapeutic Roles of Surgery and Chemotherapy for Patients With Metastatic Renal Pelvis Cancer: A SEER Based Study.
Chen WK; Wu ZG; Xiao YB; Wang QQ; Yu DD; Cai J; Zhou CF
Technol Cancer Res Treat; 2021; 20():15330338211004914. PubMed ID: 33929915
[TBL] [Abstract][Full Text] [Related]
18. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract][Full Text] [Related]
19. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.
Bandini M; Pompe RS; Marchioni M; Zaffuto E; Gandaglia G; Fossati N; Cindolo L; Montorsi F; Briganti A; Saad F; Karakiewicz PI
Int Urol Nephrol; 2018 Jan; 50(1):71-78. PubMed ID: 29129028
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study.
Wang G; Li Q; Chen W
BMC Cancer; 2021 Jul; 21(1):778. PubMed ID: 34225672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
